{"id":242,"date":"2019-12-05T08:44:40","date_gmt":"2019-12-04T22:44:40","guid":{"rendered":"https:\/\/www.tracktrial.org\/?page_id=242"},"modified":"2024-09-18T15:45:59","modified_gmt":"2024-09-18T05:45:59","slug":"about-the-study","status":"publish","type":"page","link":"https:\/\/www.claritytrial.org\/","title":{"rendered":"HOME"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"242\" class=\"elementor elementor-242\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7b7924e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7b7924e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6ebcb7b\" data-id=\"6ebcb7b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-bddfc75 elementor-widget elementor-widget-text-editor\" data-id=\"bddfc75\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<blockquote><h6 style=\"text-align: left;\">CLARITY is a randomised controlled trial that aims to establish whether Angiotensin Receptor Blockers (ARBs) reduce the severity of COVID-19.\u00a0 The trial is being conducted at sites in India and Australia and recruits patients who are admitted to hospital with COVID-19 or, in Australia only, are from a group at risk of severe disease and being monitored at home.\u00a0 In India, participants will be randomised to receive standard care plus an ARB or standard care plus matched placebo for 28 days.\u00a0 In Australia, participants will be randomised to standard care plus an ARB or standard care alone. CLARITY will assess the safety and effectiveness of ARBs for COVID-19 treatment<\/h6><\/blockquote>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b9cebb7 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"b9cebb7\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-573f753\" data-id=\"573f753\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-0796d9d elementor-widget elementor-widget-video\" data-id=\"0796d9d\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;youtube_url&quot;:&quot;https:\\\/\\\/www.youtube.com\\\/watch?v=Se3gum1Ydqw&amp;feature=youtu.be&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}\" data-widget_type=\"video.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-wrapper elementor-open-inline\">\n\t\t\t<div class=\"elementor-video\"><\/div>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<div class=\"mh-excerpt\"><p>CLARITY is a randomised controlled trial that aims to establish whether Angiotensin Receptor Blockers (ARBs) reduce the severity of COVID-19.\u00a0 The trial is being conducted <a class=\"mh-excerpt-more\" href=\"https:\/\/www.claritytrial.org\/\" title=\"HOME\">[&#8230;]<\/a><\/p>\n<\/div>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-242","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.claritytrial.org\/index.php?rest_route=\/wp\/v2\/pages\/242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.claritytrial.org\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.claritytrial.org\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.claritytrial.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.claritytrial.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=242"}],"version-history":[{"count":48,"href":"https:\/\/www.claritytrial.org\/index.php?rest_route=\/wp\/v2\/pages\/242\/revisions"}],"predecessor-version":[{"id":1814,"href":"https:\/\/www.claritytrial.org\/index.php?rest_route=\/wp\/v2\/pages\/242\/revisions\/1814"}],"wp:attachment":[{"href":"https:\/\/www.claritytrial.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}